To kick things off at this week's BIO CEO conference, conducted by the Biotech Industry Organization, Celgene's (NASDAQ:CELG) CEO Bob Hugin gave a fireside chat. In this video, Motley Fool health care bureau chief Brenton Flynn highlights one of the topics discussed -- the company's new inflammation drug Apremilast -- and one of the biggest reasons why this could be a winner over the existing crop of TNF inhibitors.